

CLINICAL DATA SUMMARY

	N	FU	CR-IM	CR-D	CR-HGD	Buried Glands	Stricture Rate
AIM-II Trial	61	30 mo	98.4%	-	-	None	0%
	50	60 mo	92%	-	-	None	0%
AIM-LGD	10	24 mo	90%	100%	-	None	0%
HGC Registry	92	12 mo	54%	80%	90%	None	0.4%
AMC-I	11	14 mo	100%	100%	-	None	0%
AMC-II	12	14 mo	100%	100%	-	None	0%
AMC Long-term FU	23	52 mo	100%	100%	-	None	
Comm. Registry	429	20 mo	77%	100%	-	None	1.1%
EURO-1	24	22 mo	96%	100%	-	None	4.0%
EURO-11	118	12+ mo	96%	100%	-	None	
Emory	27	<12 mo	100%	100%	-	None	0%
Dartmouth	25	20 mo	78%	-	-		8.0%
Henry Ford	66	varied	93%	-	-	None	6.0%
Rochester	45	21 mo	56%	87%	88%	None	2.2%
Mayo	63	24 mo	79%	89%	-	None	0%
LGD	39	24 mo	87%	95%	-	None	0%
HGD	24	23 mo	67%	79%	-	None	0%
AIM RCT (primary)	127 (RFA 84)	12 mo	77% (83%)	86% (92%)	-	5.1%	6.0%
Long-term FU	106	24 mo	93%	95%	-	3.8%	7.6%